Senti Bio extends cash runway into Q4 2024 via GeneFab deal, Q2 net loss $18.7M

Senti Biosciences, Inc.

2023-Q2 EPS reported -$0.85 revenue$2,223,000

GeneFab transaction provides up to $38M in cash by end of 2025; extends cash runway into Q4 2024.
IND for SENTI-202 (Logic Gated CAR-NK for AML) on track for 2H 2023; Phase 1 enrollment expected 2024.
Cash, equivalents & short-term investments $59.6M as of June 30, 2023.
Q2 net loss $18.7M ($0.42/share); R&D $11.0M (up from $9.2M), G&A $9.6M (down from $13.9M).
Senti subleases Alameda cGMP facility to GeneFab; co-founder Philip Lee named GeneFab CEO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 11, 2023, Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.